我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

益肾平肝方对原发性高血压患者动态血压及hs-CRP、ICAM-1、SDF-1的影响(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2016年05期
页码:
69-73
栏目:
临床研究
出版日期:
2016-10-10

文章信息/Info

Title:
Effects of Yishen Pinggan Decoction on Blood Pressure and hs-CRP、ICAM-1、SDF-1in Patients of Essential HyPertension
作者:
葛华迅朱喜英罗国东于洋郭园园王丹刘龙民
上海中医药大学附属普陀医院,上海 200062
Author(s):
GE Huaxun ZHU Xiying LUO Guodong YU Yang GUO Yuanyuan WANG Dan LIU longmin
Putuo Hospital Affliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China
关键词:
益肾平肝方 阴虚阳亢 高血压 血管内皮功能
Keywords:
Yishen Pinggan decoction Yang hyperactivity and Yin deficiency type hypertension endothelial function
分类号:
R259
DOI:
10.19288/j.cnki.issn.1000-2723.2016.05.018
文献标识码:
A
摘要:
目的〓观察益肾平肝方对原发性高血压患者动态血压及血管内皮功能的影响。方法〓收集阴虚阳亢型原发性高血压患者69例,随机分成中西药结合治疗组(益肾平肝方+科素亚)和西药对照组(科素亚)2组,用药3个月,观察患者在治疗前后的动态血压指标及hs-CRP、ICAM-1、SDF-1的变化。结果〓西药组、中西药组各项动态血压指标均较治疗前改善(P<0.05);24hSBP、24hDBP、dSBP、dDBP、nSBP治疗后中西药组疗效优于西药组(P<0.05),nDBP治疗后西药组与中西药组未见明显差异(P>0.05),hs-CRP、ICAM-1、SDF-1治疗后中西药组疗效优于西药组(P<0.05)。结论〓益肾平肝方可以协同西药降低阴虚阳亢型患者的血压,益肾平肝方协同西药能够下调阴虚阳亢型患者的hs-CRP、ICAM-1水平,上调SDF-1水平,改善高血压患者血管内皮损害。
Abstract:
Objective To observe the effects of Yishen Pinggan decoction on high blood pressure and endothelial function with some related indicators. Methods These 69 patients with Yang hyperactivity and Yin deficiency type of essential hypertension were randomly divided into 2 groups, combination of Chinese and western medication group(the Yishen Pinggan decoction and losartan potassium tablets), western medicine control group(losartan potassium tablets). Before and after 3-month treatment, the blood pressure and clinical symptoms were tested or measured. The expression of hs-CRP, ICAM-1, SDF-1 levels were measured by commercial ELISA kits. After the treatment, SPSS18. 0 statistical software was used to analysis the results. Results After three months of treatment, all the BP datas were decreased in control and treated group(P<0.05), 24hSBP, 24hDBP, dSBP, dDBP, nSBP were decreased more in the treated group(P<0.05), no significant difference in nDBP was found between control and treated group(P>0.05), which indicates the antihypertensive effect of the treated group is superior to the control group. The endothelial damage relevant indicators were found improved in control and treated group(P<0.05), hs-CRP, ICAM-1, SDF-1 were improved more in the treated group(P<0.05). Conclusion Yishen Pinggan decoction could decrease blood pressure, improve the Endothelial function which was associated with the decreasing in the expression of hs-CRP, ICAM-1 and increasing in the expression of SDF-1.

参考文献/References

[1] 中国高血压防治指南修订委员会. 中国高血压防治指南2010[J]. 中华高血压杂志,2011,19(8):701-743.
[2] 中华人民共和国卫生部. 中药新药临床研究指导原则[M]. 北京:中国医药科技出版社,2002:74-77.
[3] 陶军. 高血压血管内皮功能损害研究进展及展望[M]//孙宁玲. 高血压诊治新进展. 北京:人民军医出版社,2011:7-10.
[4] 朱喜英,常晓铁,刘龙民. 益肾平肝方对肝阳上亢型高血压大鼠血压及炎性细胞因子的影响[J]. 上海中医药杂志,2012,46(5):85-87.
[5] 朱喜英,梁贤栋,胡宗仁,等. 益肾平肝方对自发性高血压大鼠血清NO和ET含量的影响[J]. 上海中医药大学学报,2010,24(2):65-66.
[6] 孙宁玲. 中国高血压防治过程要关注个体化策略[J]. 中国医学前沿杂志(电子版),2014,6(4):1-2.
[7] 韩志奋,姜领. 高血压前期患者血管内皮功能的变化及其临床意义[J]. 蚌埠医学院学报,2014,39(10):1363-1365.
[8] 胡磊,顾国龙. C反应蛋白与原发性高血压的关系及中药干预研究进展[J]. 中国中医急症. 2011,20(3):436-437.
[9] 杨金果,李运伦,周洪雷. 钩藤和莱菔子生物碱抗高血压血管内皮细胞损伤效应[J]. 中成药,2013,35(5):889-893.
[10] 王锦生,毛伯根,吴秀清. 高血压病C-反应蛋白与动脉粥样硬化指标关系[J]. 高血压杂志,2002,10(3):255-256.
[11] Sesso HD,Buring JE,Rifai N,et al. C-reactive protein and the risk of developing hypertension[J]. JAMA,2003,290(22):2945-2951.
[12] 杜利清,秦林金,陈晓春,等. IL-6和ICAM-1与冠心病关系的研究进展[J]. 内蒙古医学杂志,2004,36(2):122-126.
[13] 黄诺,时振东,黄崭,等. 轻、中度高血压患者血清hs-CRP、ICAM-1及sCD40L水平的变化及意义[J]. 山东医药,2007,47(2):34-35.
[14] 王磊,韩伟,罗建平,等. 药物治疗老年高血压对hs-CRP和ICAM-1水平的影响[J]. 现代生物医学进展,2014,14(14):2708-2711.
[15] 程敏,QIN Gang-jian. 基质细胞衍生因子1/CXC化学趋化因子受体4信号通路:干细胞治疗缺血性疾病的新靶点[J]. 中华高血压杂志,2012,20(4):303-306.
[16] 郑浩. 基质细胞衍生因子-1α对外周血内皮祖佃胞的影响及其机制探讨[D]. 浙江:浙江大学医学院,2008.

备注/Memo

备注/Memo:
* 基金项目: 上海市普陀区卫生系统“315”工程人才培养计划(B-132);上海市普陀区中心医院重点专科(2013XK156I) 收稿日期: 2016 - 07 - 22 作者简介: 葛华迅(1981-),男,上海人,主治医师,研究方向:中西医结合防治心脑血管病。△通信作者:刘龙民,E-mail:gesptdch@126.com
更新日期/Last Update: 2016-10-10